-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU)-- BTK inhibition through the SH2 domain results in ...

-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU) ...

Six general classes of SH2 domain specificity were found which demonstrate not only the evolutionary similarities between SH2 domains in the same family of proteins but across families as well.

In biochemical and primary human cellular assays, the company’s STAT6 SH2 domain inhibitor demonstrated highly selective, picomolar potency for inhibiting STAT6 activation driven by IL-4.

Majority of human Src homology 2 (SH2) domains not only bind to proteins, but also interact with membrane lipids with high affinity and specificity. The SH2 domain-containing proteins play ...

“We have developed the first known BTK SH2 domain inhibitor, and have shown preclinically that it was effective at reducing skin inflammation in a model of CSU and has exquisite target ...

“We have developed the first known BTK SH2 domain inhibitor, and have shown preclinically that it was effective at reducing skin inflammation in a model of CSU and has exquisite target ...

"We have developed the first known BTK SH2 domain inhibitor, and have shown preclinically that it was effective at reducing skin inflammation in a model of CSU and has exquisite target selectivity not ...

-- Bruton’s tyrosine kinase (BTK) SH2 inhibitor reduced skin inflammation in a clinically-relevant model of chronic spontaneous urticaria (CSU)-- BTK inhibition through the SH2 domain results in ...